Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1991 Nov;32(5):541–549. doi: 10.1111/j.1365-2125.1991.tb03949.x

Central effects of the calcium antagonist, nifedipine.

D G McDevitt 1, D Currie 1, A N Nicholson 1, N A Wright 1, M B Zetlein 1
PMCID: PMC1368628  PMID: 1954069

Abstract

1. Central effects of the calcium antagonist, nifedipine retard (10, 20 and 40 mg) and nifedipine capsules (10 mg) were studied in 14 healthy male subjects. Two placebos and an active control drug, oxazepam (15 mg), were included. Medication was administered double-blind at 10.00 h. The effects of drugs on performance and subjective feelings were assessed before and from 1.5-2.5 h and 3.5-4.5 h after ingestion, and recordings of the electrical activity of the brain (EEG) and body sway carried out. 2. Performance was assessed using digit symbol substitution, continuous attention, letter cancellation, choice reaction time, finger tapping, immediate and short-term memory, together with critical flicker fusion and two flash fusion. The EEG was recorded with eyes open while the subjects carried out a mental arithmetic task, and with eyes closed, when they were required to relax. Body sway was recorded with eyes open and with eyes closed. Subjects assessed their mood and well-being on a series of 12 visual analogue scales. 3. Nifedipine did not alter performance levels on any of the skills tested, while oxazepam (15 mg) increased the number of errors (P less than 0.01) and reduced accuracy at continuous attention (P less than 0.01). 4. Nifedipine (10 mg) reduced total power of the EEG in the frequency range (0.5-30 Hz), and nifedipine (20 mg) increased total alpha power (7.5-13 Hz) (P less than 0.05). Oxazepam reduced alpha and increased beta 1 power (13.5-21 Hz).(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
541

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bradley C. M., Nicholson A. N. Studies on performance with aspirin and paracetamol and with the centrally acting analgesics meptazinol and pentazocine. Eur J Clin Pharmacol. 1987;32(2):135–139. doi: 10.1007/BF00542185. [DOI] [PubMed] [Google Scholar]
  2. Cortes R., Supavilai P., Karobath M., Palacios J. M. The effects of lesions in the rat hippocampus suggest the association of calcium channel blocker binding sites with specific neuronal population. Neurosci Lett. 1983 Dec 11;42(3):249–254. doi: 10.1016/0304-3940(83)90270-7. [DOI] [PubMed] [Google Scholar]
  3. Cortés R., Supavilai P., Karobath M., Palacios J. M. Calcium antagonist binding sites in the rat brain: quantitative autoradiographic mapping using the 1,4-dihydropyridines [3H]PN 200-110 and [3H]PY 108-068. J Neural Transm. 1984;60(3-4):169–197. doi: 10.1007/BF01249092. [DOI] [PubMed] [Google Scholar]
  4. Coulter D. M. Eye pain with nifedipine and disturbance of taste with captopril: a mutually controlled study showing a method of postmarketing surveillance. Br Med J (Clin Res Ed) 1988 Apr 16;296(6629):1086–1088. doi: 10.1136/bmj.296.6629.1086. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Currie D., Lewis R. V., McDevitt D. G., Nicholson A. N., Wright N. A. Central effects of beta-adrenoceptor antagonists. I--Performance and subjective assessments of mood. Br J Clin Pharmacol. 1988 Aug;26(2):121–128. doi: 10.1111/j.1365-2125.1988.tb03378.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Currie D., Lewis R. V., McDevitt D. G., Nicholson A. N., Wright N. A. Central effects of the angiotensin-converting enzyme inhibitor, captopril. I. Performance and subjective assessments of mood. Br J Clin Pharmacol. 1990 Oct;30(4):527–536. doi: 10.1111/j.1365-2125.1990.tb03810.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Das G. Fundamentals of calcium channel blockers. Int J Clin Pharmacol Ther Toxicol. 1988 Dec;26(12):575–584. [PubMed] [Google Scholar]
  8. Kleinbloesem C. H., van Brummelen P., Faber H., Danhof M., Vermeulen N. P., Breimer D. D. Variability in nifedipine pharmacokinetics and dynamics: a new oxidation polymorphism in man. Biochem Pharmacol. 1984 Nov 15;33(22):3721–3724. doi: 10.1016/0006-2952(84)90165-5. [DOI] [PubMed] [Google Scholar]
  9. Middlemiss D. N., Spedding M. A functional correlate for the dihydropyridine binding site in rat brain. Nature. 1985 Mar 7;314(6006):94–96. doi: 10.1038/314094a0. [DOI] [PubMed] [Google Scholar]
  10. Nicholson A. N., Stone B. M. The H2-antagonists, cimetidine and ranitidine: studies on performance. Eur J Clin Pharmacol. 1984;26(5):579–582. doi: 10.1007/BF00543488. [DOI] [PubMed] [Google Scholar]
  11. Nicholson A. N., Wright N. A., Zetlein M. B., Currie D., McDevitt D. G. Central effects of beta-adrenoceptor antagonists. II--Electroencephalogram and body sway. Br J Clin Pharmacol. 1988 Aug;26(2):129–141. doi: 10.1111/j.1365-2125.1988.tb03379.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Nicholson A. N., Wright N. A., Zetlein M. B., Currie D., McDevitt D. G. Central effects of the angiotensin-converting enzyme inhibitor, captopril. II. Electroencephalogram and body sway. Br J Clin Pharmacol. 1990 Oct;30(4):537–546. doi: 10.1111/j.1365-2125.1990.tb03811.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Salem S. A., McDevitt D. G. Central effects of beta-adrenoceptor antagonists. Clin Pharmacol Ther. 1983 Jan;33(1):52–57. doi: 10.1038/clpt.1983.7. [DOI] [PubMed] [Google Scholar]
  14. Salem S. A., McDevitt D. G. Central effects of single oral doses of propranolol in man. Br J Clin Pharmacol. 1984 Jan;17(1):31–36. doi: 10.1111/j.1365-2125.1984.tb04995.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Topaktas S., Onur R., Dalkara T. Calcium channel blockers and essential tremor. Eur Neurol. 1987;27(2):114–119. doi: 10.1159/000116142. [DOI] [PubMed] [Google Scholar]
  16. Turkkan J. S., Hienz R. D. Behavioral performance effects of nifedipine in normotensive and renovascular hypertensive baboons. Psychopharmacology (Berl) 1990;100(1):124–129. doi: 10.1007/BF02245802. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES